Synthesized from precursors via enzymatic pathways in presynaptic terminal. Rapidly packaged into vesicles via transporters, protecting from degradation and enabling precise release.
If you have studied synaptic transmission, you know the basic sequence: an action potential arrives at the presynaptic terminal, vesicles fuse with the membrane, and neurotransmitter floods the synaptic cleft. What that overview skips is how the transmitter gets into those vesicles in the first place — and why packaging matters at all.
Small-molecule neurotransmitters are synthesized locally in the presynaptic terminal through short enzymatic pathways starting from dietary amino acid precursors. Dopamine, for example, is made from tyrosine: the enzyme tyrosine hydroxylase converts tyrosine to DOPA, and then DOPA decarboxylase converts DOPA to dopamine. Serotonin follows an analogous two-step route from tryptophan. These enzymes are made in the cell body and transported down the axon, but the chemical reactions that produce the transmitter happen at the terminal, close to where the transmitter will be used.
Once synthesized, the transmitter must be loaded into vesicles within milliseconds. The loading is done by dedicated vesicular transporters — proteins embedded in the vesicle membrane that use the vesicle's proton gradient to pump transmitter inward. VMAT2 loads monoamines (dopamine, norepinephrine, serotonin); VAChT loads acetylcholine. The vesicle interior is acidic, and as protons leak out down their gradient, the transporter exchanges them for neurotransmitter molecules. This concentrates the transmitter to millimolar levels inside the vesicle.
The two key functions of vesicular storage are protection and quantization. Cytoplasmic neurotransmitters are vulnerable: monoamine oxidase (MAO) and other enzymes in the cytoplasm would degrade them rapidly if they were left free. The vesicle membrane shields the transmitter from these enzymes. Second, because each vesicle holds a roughly fixed number of transmitter molecules, release of a single vesicle produces a miniature postsynaptic potential of predictable amplitude — a "quantum." Larger signals are built by releasing more quanta simultaneously, not by varying the concentration per vesicle. This quantal logic makes synaptic transmission reliable and graded.
Disrupting any step in this pathway has dramatic consequences. Drugs that block vesicular loading (such as reserpine, which inhibits VMAT2) deplete monoamine stores and were among the first antidepressant-adjacent compounds studied. Understanding synthesis and storage is therefore not merely descriptive — it is the mechanistic foundation for understanding how drugs, toxins, and disease states alter neurotransmission.